GLP-1 Drugs Reduce BMI and Insulin Needs in Youth with Type 1 Diabetes and Obesity | Research

The takeaway

GLP-1 receptor agonists reduced BMI and total daily insulin dose in youth with type 1 diabetes and obesity, offering metabolic benefits while preserving glycemic control.

Less insulin, less weight
GLP-1 drugs reduced both BMI and insulin dose in T1D youth while maintaining blood sugar control

What the researchers found

GLP-1 RAs reduced BMI and total daily insulin dose in youth with T1D and obesity while maintaining glycemic control.

Why it matters

Youth T1D + obesity is a growing problem with no good treatment options. GLP-1 drugs could address both by reducing insulin requirements and promoting weight loss.

How the study worked

Study evaluating GLP-1 RA effects on BMI, insulin dose, and glycemic control in youth with T1D and obesity.

What this study cannot tell us

Specific study details limited in abstract. Youth T1D populations are heterogeneous. Long-term effects unknown.

How to read the evidence

Clinical study with relevant outcomes for a challenging population.

When this study was published

Published in 2025.

The bigger picture

Extending GLP-1 drug benefits to youth with T1D opens a new therapeutic avenue for a population with limited pharmacological options.

Questions still open

Should GLP-1 drugs be routinely considered for obese T1D youth?
Does insulin dose reduction improve long-term metabolic outcomes?
Are there concerns about GLP-1 drug effects on growth in youth?

Common questions

Can GLP-1 drugs help young people with type 1 diabetes?

For youth with T1D who also have obesity, GLP-1 drugs reduced both weight and insulin needs while keeping blood sugar controlled — breaking the cycle of insulin-caused weight gain.

Is it safe for children?

This study supports its use in youth, but long-term safety data in growing children are still limited. It should be used under specialist supervision.

Read the original research

GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.

Journal of pediatric endocrinology & metabolism : JPEM, 39(2), 166-172

View on PubMed ↗Publisher’s paper ↗

Citation

Gonzalez, Frances; Reid, Mark W; Garcia, Jaquelin Flores; Raymond, Jennifer K; Chao, Lily C. (2026). GLP-1 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: a retrospective cohort study.. Journal of pediatric endocrinology & metabolism : JPEM, 39(2), 166-172. https://doi.org/10.1515/jpem-2025-0568